Exploring health related quality of life for women with breast cancer in Ireland and Québec, Canada throughout the COVID-19 pandemic.

Publication date: Feb 01, 2025

The long-term consequences from the COVID-19 pandemic on breast cancer (BC) is highly unknown, however persisting unmet needs and psychosocial difficulties are likely. The objectives of this study were to evaluate the change in health-related quality of life (HR-QoL) from the pandemic to post-pandemic for women living with a diagnosis of BC and to assess the association between COVID-19 stressor impact and HR-QoL in Ireland and QucE9bec, Canada. Women with a diagnosis of BC were initially enrolled in the cohort study. HR-QoL was assessed during the pandemic (2020-2021) and post-pandemic periods (2022). COVID-19 stressor impact was computed post-pandemic, and change in HR-QoL during and post-pandemic was compared between Ireland and QucE9bec using independent t-tests. Multivariable analysis of covariance (ANCOVA) was used to evaluate the association between COVID-19 stressor impact and changes in HR-QoL, and compare it between Ireland and QucE9bec. 405 participants were included from both settings (Ireland n = 267; QucE9bec n = 138). The average HR-QoL improved from the COVID-19 pandemic to post-pandemic, and there were no differences between Ireland and QucE9bec. Women with high COVID-19 stressor impact (18. 9% of participants) had a significantly smaller improvement in their overall HR-QoL compared to those with low COVID-19 stressor impact, and this was evident in Ireland (p 

Open Access PDF

Concepts Keywords
Canada Adult
Ireland Aged
Pandemic Breast cancer
Women Breast Neoplasms
Cohort Studies
COVID-19
COVID-19
Cross-country comparison
Female
Humans
Ireland
Middle Aged
Pandemics
Psycho-oncology
Psychosocial stressors
Quality of Life
Quality of life
Quebec
SARS-CoV-2
Stress, Psychological
Surveys and Questionnaires

Semantics

Type Source Name
disease IDO quality
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH COVID-19 pandemic
disease IDO country
disease MESH morbidity
drug DRUGBANK Coenzyme M
disease MESH cancer
drug DRUGBANK Aspartame
disease MESH education level
disease MESH death
disease MESH anxiety
disease MESH depressive symptoms
disease MESH insomnia
disease IDO intervention
drug DRUGBANK Etoperidone
disease MESH privacy
disease MESH psychological distress
disease MESH Lifestyle
pathway REACTOME Release
disease MESH chronic illness
disease MESH symptom burden
pathway REACTOME Reproduction
disease MESH Stress Psychological

Original Article

(Visited 2 times, 1 visits today)